AIRCHILL · Investor Data Room
Last reviewed 15 August 2026 · Trust Center / change history
Due diligence should be easier than the pitch.
A structured diligence hub for Medical Cooling / AIRCHILL covering product, evidence, intellectual property, regulatory strategy, reimbursement, market, financial planning, execution risks and the materials that remain restricted or incomplete.
Room map
Eight diligence workstreams.
The room is organised the way a professional MedTech diligence process usually unfolds: company and transaction first, then product, evidence, IP, regulatory, market access, financials and execution risk.
Master document register
What exists, what is restricted, and what is still a gap.
“Available” means a diligence source is currently published on MedicalCooling.com or in an official public register. “Restricted” means the existing material is described by the company but is not published here. “Gap” means the current public materials explicitly identify the item as unresolved or not yet documented.
Fast diligence paths
Open the evidence behind the investment case.
These are the highest-signal public paths for a first investor review before requesting confidential transaction documents.
AIRCHILL
Understand the development-stage platform, system thesis and intended emergency-care workflow. Open →
Evidence register
Review what the project supports, what belongs only to the broader literature and what still needs validation. Open →
Research register
Inspect the broader hypothermia evidence landscape and ongoing trial context. Open →
Regulatory pathway
Review current planning assumptions without treating them as granted classification or approval. Open →
EMS reimbursement
Review payer, procurement and reimbursement structures instead of relying on a generic TAM slide. Open →
Sources & assumptions
Trace modelling inputs, transferred sensitivities and known data gaps. Open →
Key diligence flags
Material issues already surfaced before an investor asks.
These are not hidden in footnotes. They are the issues most likely to affect valuation, closing conditions or the next value-inflection milestone.
Concentrated ownership simplifies the corporate IP step
The granted European and US patents are held solely by founder and inventor Fabian Temme. The university is no longer part of the patent ownership structure, avoiding institutional co-ownership and multi-party negotiations. The remaining step is a direct assignment or exclusive, worldwide, sublicensable licence from the sole patent holder to the operating company as part of the financing structure.
Clinical benefit is not established
The existing evidence section explicitly distinguishes mechanism and technical findings from future clinical efficacy. Prior airway-cooling trials in the field are part of the risk context.
Class IIb remains preliminary
The public investor material does not present the classification as final and allocates material funding to QMS, regulatory affairs and verification/validation.
Founder-capacity terms need documentation
The investor material states that weekly hours, compensation, transition date and employment/IP terms are not yet documented.
Restricted vault
Confidential materials belong behind controlled access.
The public room is deliberately not a file dump. Transaction-sensitive documents should move into a controlled-access vault with named investor access, NDA status, document versioning and a download/audit trail.
No password, cap table, bank document, investor deck, financial workbook or personal employment document is published on this page.
- 01Investor deck 2026
- 022027–2031 financial model · low / base / high
- 03Venture, bank and development-bank business plans
- 04Cap table / financing history / transaction documents
- 05IP assignment or licence documentation once executed
- 06Corporate, employment and board/shareholder materials
- 07Controlled technical/QMS records as they mature
Investor access
Start with the public evidence. Request the restricted room when the fit is real.
The objective is a faster, cleaner diligence process: fewer unsupported claims, fewer hidden surprises and a clear distinction between public evidence, confidential documents and unresolved work.
AIRCHILL is a development-stage medical technology project. This data room does not represent regulatory approval, established clinical efficacy, a securities offering or a guarantee of future financing or performance.